Anixa Biosciences Enhances Treasury Strategy by Investing in Bitcoin

Anixa Biosciences, a cancer-focused biotech firm, has announced plans to incorporate Bitcoin into its treasury strategy to strengthen its financial position and create added value for its shareholders.

In a Nov. 22 press release, the San Jose-based biotech company revealed it will allocate a portion of its treasury to Bitcoin, citing the cryptocurrency’s inflation-resistant qualities. The decision, approved by the company’s board, is part of a broader initiative to diversify its cash holdings while continuing its focus on clinical advancements and shareholder returns.

Strategic Financial Management and Growth

Anixa emphasized its strong balance sheet and excess cash, which enable the company to pursue innovative financial strategies. The addition of Bitcoin to its treasury reserves represents a diversification effort while ensuring the company can remain focused on its core goal—advancing clinical trials and maintaining a robust return on investment for its shareholders.

Mike Catelani, President and CFO of Anixa, commented on the growing importance of Bitcoin, saying, “With Bitcoin’s growing recognition as a mainstream asset class, we believe it represents a valuable addition to our treasury reserve strategy. The approval of Bitcoin ETFs and increasing participation from institutional investors highlight its rising importance in global markets.”

Rising Trend Among Public Companies

Anixa’s move is part of a larger trend among public companies integrating Bitcoin into their financial portfolios. Several companies, including Genius Group, an AI firm, recently announced $4 million in Bitcoin purchases, bringing their holdings to 153 BTC. Genius Group’s strategy focuses on a “Bitcoin-first” approach, with the goal of allocating 90% or more of its reserves into Bitcoin.

Other major firms, including MicroStrategy and Nasdaq-listed Acurx, have also expanded their Bitcoin holdings, viewing the asset as a hedge against inflation and a store of value, while supporting innovation in technology.

Impact on Anixa’s Stock

Following the announcement, Anixa Biosciences’ shares surged by 7.84% in pre-market trading, reflecting investor enthusiasm over the company’s new financial approach and the growing institutional adoption of Bitcoin. The integration of Bitcoin into its treasury is seen as a step toward more prudent financial management and the potential for increased shareholder value.

This strategic financial move positions Anixa Biosciences alongside other companies capitalizing on the financial benefits of Bitcoin while continuing to focus on their primary business objectives.